AOD 9604 (5MG)

AOD-9604 — the modified C-terminal hGH 176-191 fragment with an additional N-terminal tyrosine — supplied by BioFusion as a vacuum-sealed lyophilized 5mg vial for hGH-fragment research chemistry.

Research context

AOD-9604 is the (Tyr-)hGH 177-191 modified fragment — a 16-residue research peptide derived from the lipolytic-active C-terminal region of human growth hormone, with an additional tyrosine residue at the N-terminus relative to the unmodified HGH Fragment 176-191. The added tyrosine enables iodination-based labeling research and provides a UV chromophore for HPLC tracking. Frequently included in lipolysis-research panels.

Synthesis & documentation

Produced by solid-phase peptide synthesis using Fmoc protecting-group strategy in a U.S.-based ISO 9001:2008 facility. Each lot is verified for identity (LC-MS), purity (reverse-phase HPLC-UV ≥99.0%), moisture (Karl Fischer), and counter-ion (ion chromatography). The signed Certificate of Analysis ships with every order; full lot archive on the COA library.

Storage & handling

Lyophilized AOD-9604 is stable at −20 °C for the printed shelf life. After reconstitution, the standard 14-day-at-2-8 °C reference window applies; avoid freeze-thaw cycling. The added N-terminal tyrosine is photo-oxidation-sensitive — protect from direct light during handling. The reconstitution calculator handles working-concentration math.

Why BioFusion

The “AOD-9604 vs HGH Fragment 176-191” distinction is sometimes blurred on third-party listings — but the additional N-terminal tyrosine in AOD-9604 is a meaningful structural difference. BioFusion’s AOD-9604 is verified by LC-MS to confirm the correct molecular weight and residue count. Batch transparency ledger publishes purity and synthesis-date per release. Bulk discounts at three+; members save 25%.

For research and laboratory use only. This product is not a drug, food, or cosmetic, and is not intended for diagnostic, therapeutic, or in vivo human use.